US8710221B2 - Process and intermediates for preparing lapatinib - Google Patents

Process and intermediates for preparing lapatinib Download PDF

Info

Publication number
US8710221B2
US8710221B2 US14/030,705 US201314030705A US8710221B2 US 8710221 B2 US8710221 B2 US 8710221B2 US 201314030705 A US201314030705 A US 201314030705A US 8710221 B2 US8710221 B2 US 8710221B2
Authority
US
United States
Prior art keywords
compound
formula
lapatinib
salt
mecn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US14/030,705
Other versions
US20140024829A1 (en
Inventor
Yung-fa Chen
Julian Paul Henschke
Xiaoheng Zhang
Yijing Chen
ChunFang XU
Yong MU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scinopharm Taiwan Ltd
Original Assignee
Scinopharm Taiwan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2011/000493 external-priority patent/WO2011116634A1/en
Application filed by Scinopharm Taiwan Ltd filed Critical Scinopharm Taiwan Ltd
Priority to US14/030,705 priority Critical patent/US8710221B2/en
Assigned to SCINOPHARM TAIWAN, LTD. reassignment SCINOPHARM TAIWAN, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, YUNG-FA, HENSCHKE, JULIAN PAUL, CHEN, YIJING, MU, Yong, XU, CHUNFANG, ZHANG, XIAOHENG
Publication of US20140024829A1 publication Critical patent/US20140024829A1/en
Application granted granted Critical
Publication of US8710221B2 publication Critical patent/US8710221B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention is related to a process of making lapatinib, salts and novel intermediates thereof
  • Lapatinib has the structural formula (I) and chemical name N-[3-chloro-4-[(3-fluorophenyl) methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine.
  • Lapatinib is an orally administered small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, used in the form of ditosylate salt to treat advanced or metastatic breast cancer and other solid tumors which were treated by Anthracyclines, Taxanes and Trastuzumab (Herceptin®).
  • Lapatinib ditosylate was approved by the FDA in 2007 and the EMEA in 2008 and is marketed by GlaxoSmithKline (GSK) under the trade name of Tykerb® in the USA and Tyverb® in Europe.
  • GSK GlaxoSmithKline
  • a process for preparing lapatinib or its pharmaceutically acceptable salt comprising converting a compound of formula (X):
  • Another aspect of the present invention is a compound of formula (X) as shown above or its salts, preferably an HCl salt.
  • the compound of formula (X) is stable and suitable for industrial production.
  • the compound of formula (X) can provide higher selectivity and yield for the process of preparing lapatinib.
  • the compound of formula (X) is synthesized by reacting a compound of formula (IX)
  • FIG. 1 shows the IR spectrum of the compound of formula (X).
  • FIG. 2 shows the DSC of the compound of formula (X).
  • FIG. 3 shows the TGA of the compound of formula (X).
  • FIG. 4 shows the 1 H NMR spectrum of the compound of formula (X).
  • lapatinib is produced by
  • the solvent in step i) can be tetrahydrofuran (THF), acetonitrile (MeCN), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidone (NMP), or tetramethylurea (TMU) and is preferably selected from THF, DMF, and MeCN, each having water content of no more than 100 ppm as determined by Karl-Fischer (KF) titration, most preferably MeCN with a KF value of no more than 100 ppm.
  • KF Karl-Fischer
  • (X) is reacted with the compound of formula (VII) in a polar solvent such as DMF, DMAC, DMI, NMP or TMU to give a homogeneous reaction solution. After the reaction is complete, water is added to precipitate the (IV).HCl. The (IV).HCl is then isolated by filtration.
  • a polar solvent such as DMF, DMAC, DMI, NMP or TMU
  • novel intermediate of the compound of formula (X) provide high yield for the process of preparing lapatinib.
  • DSC DSC-TA Q2000; condition: 40° C. to 200° C. (10° C./min)
  • TGA TGA-TA Q500; condition: Room temperature to 300° C. (10° C./min)
  • Lapatinib ditosylate was converted to its free base form, lapatinib, by washing the THF solution of lapatinib ditosylate with aqueous NaOH followed by concentration to obtain lapatinib solid.
  • Lapatinib ditosylate (5.0 g, 5.4 mmol, 96.5% HPLC purity with the maximum individual impurity at 0.8%) was dissolved in DMSO (10 mL) at 70° C. (internal temperature). MeCN (10 mL) was added dropwise into the mixture at 70-80° C. (internal temperature) and was stirred at this temperature for 1 h. Over a 4 h period the mixture was cooled to room temperature. MeCN (30 mL) was added dropwise, and the mixture was stirred for 1 h, then filtered and washed with MeCN (10 mL). The filter cake was dried under vacuum at 60° C. for 16 h to give 4.0 g lapatinib ditosylate as crystalline Form 1 (as disclosed in U.S. Pat. No. 7,157,466 B2) with 99.6% HPLC purity in 78% HPLC yield.
  • Lapatinib ditosylate (3 g, 3.25 mmol, 99.3% HPLC purity was dissolved in DMF (18 mL) at 80° C. and stirred for 1 hour. The mixture was hot-filtered. MeCN (18 mL) was added into the filtrate at 80° C. The temperature was cooled to 70° C. and crystal precipitated. The mixture was kept at 70° C. for 1 h and then 60° C. for 1 h. The mixture was further cooled to 0° C. and stirred for 2 h. The crystals of lapatinib ditosylate were isolated by filtration and were dried at 40° C. under vacuum overnight. Lapatinib ditosylate (2.5 g, 2.70 mmol, 83% yield) with 99.9% HPLC purity was obtained. XRPD analysis indicated that this was Form 2 as disclosed in WO 2009/079541 A1.

Abstract

A compound of formula (X):
Figure US08710221-20140429-C00001
which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. patent application Ser. No. 13/582,875 which is a U.S. national phase application based on PCT/CN2011/000493 filed on Mar. 23, 2011, which claims priority from U.S. Provisional Application No. 61/316,425 filed on Mar. 23, 2010. The entire content of the related applications is incorporated herein as reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is related to a process of making lapatinib, salts and novel intermediates thereof
Lapatinib has the structural formula (I) and chemical name N-[3-chloro-4-[(3-fluorophenyl) methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine.
Figure US08710221-20140429-C00002
Lapatinib is an orally administered small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, used in the form of ditosylate salt to treat advanced or metastatic breast cancer and other solid tumors which were treated by Anthracyclines, Taxanes and Trastuzumab (Herceptin®). Lapatinib ditosylate was approved by the FDA in 2007 and the EMEA in 2008 and is marketed by GlaxoSmithKline (GSK) under the trade name of Tykerb® in the USA and Tyverb® in Europe.
There is a need for an improved process of making lapatinib and its pharmaceutically acceptable salts.
SUMMARY OF THE INVENTION
In accordance with one aspect of the present invention, a process for preparing lapatinib or its pharmaceutically acceptable salt comprising converting a compound of formula (X):
Figure US08710221-20140429-C00003
to lapatinib or its pharmaceutically acceptable salt.
Another aspect of the present invention is a compound of formula (X) as shown above or its salts, preferably an HCl salt. The compound of formula (X) is stable and suitable for industrial production. In addition, the compound of formula (X) can provide higher selectivity and yield for the process of preparing lapatinib.
In accordance with yet another aspect of the present invention, the compound of formula (X) is synthesized by reacting a compound of formula (IX)
Figure US08710221-20140429-C00004
with SOCl2 in the presence of dimethylformamide (DMF).
The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of the disclosure. For a better understanding of the invention, its operating advantages, and specific objects attained by its use, reference should be had to the drawing and descriptive matter in which there are illustrated and described preferred embodiments of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
In the drawings:
FIG. 1 shows the IR spectrum of the compound of formula (X).
FIG. 2 shows the DSC of the compound of formula (X).
FIG. 3 shows the TGA of the compound of formula (X).
FIG. 4 shows the 1H NMR spectrum of the compound of formula (X).
 DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS
In one embodiment, lapatinib is produced by
i) reacting the compound of formula (X)
Figure US08710221-20140429-C00005
with 3-chloro-4-(3-fluorobenzyloxy)aniline (VII)
Figure US08710221-20140429-C00006
in a solvent with or without a base to produce the compound of formula (IV) or its salt
Figure US08710221-20140429-C00007
and
ii) reductively aminating the compound of formula (IV) or its salt with 2-(methylsulfonyl)ethanamine (VIII) or its salt (e.g., (VIII).HCl) to provide lapatinib.
The solvent in step i) can be tetrahydrofuran (THF), acetonitrile (MeCN), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidone (NMP), or tetramethylurea (TMU) and is preferably selected from THF, DMF, and MeCN, each having water content of no more than 100 ppm as determined by Karl-Fischer (KF) titration, most preferably MeCN with a KF value of no more than 100 ppm.
In another embodiment, (X) is reacted with the compound of formula (VII) in a polar solvent such as DMF, DMAC, DMI, NMP or TMU to give a homogeneous reaction solution. After the reaction is complete, water is added to precipitate the (IV).HCl. The (IV).HCl is then isolated by filtration.
The novel intermediate of the compound of formula (X) provide high yield for the process of preparing lapatinib.
EXAMPLES
The following examples are provided for illustrating, but not limiting, the present invention.
Example 1 Synthesis of 5-(4-oxo-3,4-dihydroquinazolin-6-yl)furan-2-carbaldehyde (IX)
Figure US08710221-20140429-C00008
A 5:2 v/v solvate mixture of Dimethyl sulfoxide (DMSO) and H2O (1400 mL) was degassed for 30 min at ambient temperature using nitrogen. Under an atmosphere of nitrogen, 5-formylfuran-2-ylboronic acid ((VIa); 26.8 g, 193 mmol) was added into this mixture and dissolved. [HP(t-Bu)3]BF4 (840 mg, 2.94 mmol) and palladium acetate (Pd(OAc)2, 680 mg, 2.94 mmol) was added and the mixture was stirred at ambient temperature for 20 min. Then, potassium acetate (AcOK, 18.8 g, 192 mmol) was added into the reactor and was stirred for 20 min. 6-Iodoquinazolin-4(3H)-one ((Va); 40 g, 147 mmol) was added. Then the reaction mixture was heated to 80±5° C. (internal temperature). Upon completion of the reaction (HPLC), the reaction mixture was hot-filtered, then hot water (400 mL, 80±5° C.) was added into the filtrate. This was slowly cooled to 0-15° C. (solid started to precipitate at 70° C. (internal temperature)) and was then filtered. The filter cake was washed with H2O (80 mL), then with MeCN (60 mL), and dried in vacuo at 60±5° C. for 6 h to provide 5-(4-oxo-3,4-dihydroquinazolin-6-yl)-furan-2-carbaldehyde ((IX); 34.6 g, 144 mmol) with 99.7% HPLC purity in 97.6% HPLC yield. 1H NMR (300 MHz, d6-DMSO): δ 7.47 (d, J=3.8 Hz, 1H), 7.69 (d, J=3.8 Hz, 1H), 7.77 (d, J =8.6 Hz, 1H), 8.17 (s, 1H), 8.27 (dd, J=8.6, 2.1 Hz, 1H), 8.52 (d, J=2.1 Hz, 1H), 9.66 (s, 1H); 13C NMR (75 MHz, CDCl3): δ 110.5, 122.6, 123.9, 126.0, 127.5, 129.0, 131.4, 147.1, 150.1, 152.7, 157.6, 161.2, 178.8; ESI-MS, Pos: [M+H]+m/z 241; IR (cm−1): 1713, 1671, 1604, 1462; m.p.: 267° C.
Example 2 Synthesis of compound of formula (X)
Figure US08710221-20140429-C00009
DMF (8.7 mL, 116 mmol, 0.16 eq.) was added to a compound of formula (IX) (174.0 g, 725 mmol, 1.0 eq.) in thionyl chloride (1740 mL) and the mixture was stirred and heated to 55-60° C. for 1 hour then increased temperature to 80° C. and stirred at this temperature for not less than 2 hours. Excess thionyl chloride was removed by distillation under reduced pressure and the residue was azeotropically-distilled with toluene (1740 mL) twice (controlled temperature at 80-90° C.) to become about 400 mL. Toluene (350 mL) and n-heptane (1400 mL) were added to the residue and stirred at ambient temperature for not less than 2 hours. The batch was filtered and the wet cake was washed with n-heptane (500 mL) and dried at 40±5° C. under vacuo for 10 hours to afford bright yellow solid compound of formula (X) (212 g, 83.5% yield with 91.8% purity). 1H NMR (400 MHz, CDC13) δ: 9.07 (s, 1H), 8.55 (d, J=1.8 Hz, 1H), 8.30 (dd, J=8.8, 1.8 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 6.92 (d, J=3.5 Hz, 1H), 6.81 (s, 1H), 6.76 (d, J=3.5 Hz, 1H).
The IR spectrum, DSC, TGA, and 1H NMR of the compound of formula (X) are respectively shown in FIGS. 1-4. The conditions used by DSA, TGA, IR, and NMR tests are provided below respectively:
DSC: DSC-TA Q2000; condition: 40° C. to 200° C. (10° C./min)
TGA: TGA-TA Q500; condition: Room temperature to 300° C. (10° C./min)
IR: Nicolet FT-IR Avatar 360; condition: KBr Pellet
NMR: Bruker AVANCE III 400 MHz; condition: in CDCl3, 298 K
Example 3 Synthesis of Compound of Formula (IV)
Figure US08710221-20140429-C00010
3.0 g of compound of formula (X) and THF (24 mL) were added into flask, and then heated to reflux. 3-chloro-4-(3-fluorobenzyloxy) benzenamine ((VII), 2.4 g) THF (12 mL) solution was added dropwise. The reaction mixture was kept stirring and reflux for 1 hour. Then H2O (3 mL) was added and kept reflux for 0.5 h. The mixture was cooled to 25° C. in water bath. The mixture was alkalized to pH=8-9 with 30% K3PO4aq. The organic phase was separated and heated to reflux, and then n-heptane (12 mL) was added dropwise. The mixture was cooled to ambient temperature and stirred for 2 hours at ambient temperature. The mixture was filtered, and the filter cake was washed with THF/heptane (1: 1, 4.5 mL) and was then dried under vacuum at 80±5° C. for 4 h to give 3.6 g (IV) with 96.4% HPLC purity.
Example 4 Synthesis of N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl) ethylamino)methyl)furan-2-yl)quinazolin-4-amine ditosylate (lapatinib ditosylate)
Figure US08710221-20140429-C00011
To a suspension of 2-(methylsulfonyl)ethanamine hydrochloride (1.3 g, 8.1 mmol) and compound of formula (IV) (3.0 g, 6.3 mmol) in THF (60 mL) was added DIPEA (4.7 mL). After stirred at ambient temperature for 0.5 hours, sodium triacetoxyborohydride (4.0 g, 24.3 mmol) was added and the mixture was stirred at 20±5° C. (external temperature) until HPLC showed the completion of the reaction. Reaction mixture was quenched with H2O (9 mL, 3 P) in ice-water bath to keep Tin <25° C. The organic phase was washed with 10% aqueous NH4Cl (6 mL), filtered, treated with p-TsOH (4.8 g, 25.2 mmol) and heated to reflux for 2 h. The mixture was cooled to ambient temperature and stirred for 15 h at ambient temperature. The mixture was filtered, and the filter cake was washed by 1:1 (v/v) THF/H2O (4.5 mL), dried under vacuum at 80±5° C. for 6 h to give crude lapatinib ditosylate (3.4 g, HPLC purity: 95.2%). Lapatinib ditosylate 1H NMR (300 MHz, d6-DMSO): δ 11.41(s, 2H), 9.33 (s, 3H), 9.04 (d, J=1.3 Hz, 2H), 8.93 (s, 2H), 8.41 (dd, J=8.8, 1.6 Hz, 2H), 7.91 (d, J=2.6 Hz, 2H), 7.54-7.41 (m, 9H), 7.37-7.27 (m, 6H), 7.25 (d, J=3.4 Hz, 2H), 7.22-7.13 (m, 2H), 7.08 (dd, J=8.4, 0.6 Hz, 8H), 6.87 (d, J=3.5 Hz, 2H), 5.29 (s, 4H), 4.46 (s, 4H), 3.65-3.51 (m, 4H), 3.51-3.38 (m, 4H), 2.26 (s, 12H).
Lapatinib ditosylate was converted to its free base form, lapatinib, by washing the THF solution of lapatinib ditosylate with aqueous NaOH followed by concentration to obtain lapatinib solid. Lapatinib: 1H NMR (300 MHz, d6-DMSO): δ 2.98 (t, J=6.75 Hz, 1H), 3.04 (s, 1H), 3.29 (t, J=6.6 Hz, 1H), 3.83 (s, 1H), 5.28 (s, 1H), 6.50 (d, J=3.0 Hz, 1H), 7.08 (d,J=3.3 Hz, 1H), 7.20 (m, 1H), 7.33 (m, 4H), 7.48 (m, 1H), 7.76 (m, 1H), 7.80 (d, J=9 Hz, 1H), 8.04 (d, J=2.75 Hz, 1H), 8.17 (dd, J=8.7 Hz, J=1.8 Hz, 1H), 8.56 (s, 1H), 8.75 (d, J=1.8 Hz, 1H).
Example 5a Purification of Lapatinib Ditosylate
Lapatinib ditosylate (5.0 g, 5.4 mmol, 96.5% HPLC purity with the maximum individual impurity at 0.8%) was dissolved in DMSO (10 mL) at 70° C. (internal temperature). MeCN (10 mL) was added dropwise into the mixture at 70-80° C. (internal temperature) and was stirred at this temperature for 1 h. Over a 4 h period the mixture was cooled to room temperature. MeCN (30 mL) was added dropwise, and the mixture was stirred for 1 h, then filtered and washed with MeCN (10 mL). The filter cake was dried under vacuum at 60° C. for 16 h to give 4.0 g lapatinib ditosylate as crystalline Form 1 (as disclosed in U.S. Pat. No. 7,157,466 B2) with 99.6% HPLC purity in 78% HPLC yield.
Example5b Purification of Lapatinib Ditosylate
Lapatinib ditosylate (3 g, 3.25 mmol, 99.3% HPLC purity was dissolved in DMF (18 mL) at 80° C. and stirred for 1 hour. The mixture was hot-filtered. MeCN (18 mL) was added into the filtrate at 80° C. The temperature was cooled to 70° C. and crystal precipitated. The mixture was kept at 70° C. for 1 h and then 60° C. for 1 h. The mixture was further cooled to 0° C. and stirred for 2 h. The crystals of lapatinib ditosylate were isolated by filtration and were dried at 40° C. under vacuum overnight. Lapatinib ditosylate (2.5 g, 2.70 mmol, 83% yield) with 99.9% HPLC purity was obtained. XRPD analysis indicated that this was Form 2 as disclosed in WO 2009/079541 A1.
The invention is not limited by the embodiments described above which are presented as examples only but can be modified in various ways within the scope of protection defined by the appended patent claims.

Claims (8)

We claim:
1. A process for preparing lapatinib or a pharmaceutically acceptable salt thereof comprising converting a compound of formula (X):
Figure US08710221-20140429-C00012
to lapatinib:
Figure US08710221-20140429-C00013
or the pharmaceutically acceptable salt thereof, wherein the step of converting the compound of formula (X) comprises:
i) reacting the compound of formula (X):
Figure US08710221-20140429-C00014
 with a compound of formula (VII):
Figure US08710221-20140429-C00015
 in a solvent to produce a compound of formula (IV) or its salt
Figure US08710221-20140429-C00016
 and
ii) reductively aminating the compound of formula (IV) or its salt with a compound of formula (VIII)
Figure US08710221-20140429-C00017
 or its salt to provide lapatinib or the pharmaceutically acceptable salt thereof.
2. The process of claim 1 wherein the solvent is selected from the group consisting of tetrahydrofuran (THF), acetonitrile (MeCN), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidone (NMP), tetramethylurea (TMU), and combinations thereof.
3. The process of claim 1 wherein the solvent is selected from THF, DMF, MeCN, each having a water content of no more than 100 ppm as determined by Karl-Fischer (KF) titration, and combinations thereof.
4. The process of claim 1 wherein the solvent is MeCN with a KF value of no more than 100 ppm.
5. The process of claim 1 further comprising a step of reacting laptinib with p-toluenesulfonic acid to produce lapatinib ditosylate.
6. A compound of formula (X):
Figure US08710221-20140429-C00018
or a salt thereof.
7. The compound of claim 6 wherein the salt is a hydrochloric acid salt of the compound of formula (X).
8. A process for preparing a compound of formula (X):
Figure US08710221-20140429-C00019
comprising a step of reacting a compound of formula (IX):
Figure US08710221-20140429-C00020
with SOCl2 in the presence of toluene.
US14/030,705 2010-03-23 2013-09-18 Process and intermediates for preparing lapatinib Active US8710221B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/030,705 US8710221B2 (en) 2010-03-23 2013-09-18 Process and intermediates for preparing lapatinib

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31642510P 2010-03-23 2010-03-23
PCT/CN2011/000493 WO2011116634A1 (en) 2010-03-23 2011-03-23 Process and intermediates for preparing lapatinib
US201213582875A 2012-09-05 2012-09-05
US14/030,705 US8710221B2 (en) 2010-03-23 2013-09-18 Process and intermediates for preparing lapatinib

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/582,875 Continuation-In-Part US8563719B2 (en) 2010-03-23 2011-03-23 Process and intermediates for preparing lapatinib
PCT/CN2011/000493 Continuation-In-Part WO2011116634A1 (en) 2010-03-23 2011-03-23 Process and intermediates for preparing lapatinib

Publications (2)

Publication Number Publication Date
US20140024829A1 US20140024829A1 (en) 2014-01-23
US8710221B2 true US8710221B2 (en) 2014-04-29

Family

ID=49947095

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/030,705 Active US8710221B2 (en) 2010-03-23 2013-09-18 Process and intermediates for preparing lapatinib

Country Status (1)

Country Link
US (1) US8710221B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713485B2 (en) 1998-01-12 2004-03-30 Smithkline Beecham Corporation Heterocyclic compounds
AU2005203303A1 (en) 2000-06-30 2005-08-18 Glaxo Group Limited Quinazoline ditosylate salt compounds
WO2006066267A2 (en) 2004-12-17 2006-06-22 Smithkline Beecham (Cork) Limited Cancer treatment method
US7157466B2 (en) 2000-06-30 2007-01-02 Smithkline Beecham (Cork) Limited Quinazoline ditosylate salt compounds
WO2009042613A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
WO2009079541A1 (en) 2007-12-18 2009-06-25 Smithkline Beecham (Cork) Limited Quinazoline ditosylate anhydrate forms
WO2010017387A2 (en) 2008-08-06 2010-02-11 Teva Pharmaceutical Industries Ltd. Lapatinib intermediates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713485B2 (en) 1998-01-12 2004-03-30 Smithkline Beecham Corporation Heterocyclic compounds
US6727256B1 (en) 1998-01-12 2004-04-27 Smithkline Beecham Corporation Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AU2005203303A1 (en) 2000-06-30 2005-08-18 Glaxo Group Limited Quinazoline ditosylate salt compounds
US7157466B2 (en) 2000-06-30 2007-01-02 Smithkline Beecham (Cork) Limited Quinazoline ditosylate salt compounds
WO2006066267A2 (en) 2004-12-17 2006-06-22 Smithkline Beecham (Cork) Limited Cancer treatment method
WO2009042613A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]
WO2009079541A1 (en) 2007-12-18 2009-06-25 Smithkline Beecham (Cork) Limited Quinazoline ditosylate anhydrate forms
WO2010017387A2 (en) 2008-08-06 2010-02-11 Teva Pharmaceutical Industries Ltd. Lapatinib intermediates

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
English Translation of Search Report of the Taiwan Counterpart Patent Application No. TW100109970.
Organic Process Research & Development 2003, 7, 733-742.
Organic Process Research & Development 2005, 9, 198-205.
Organic Process Research & Development 2009, 13, 429-433.
Petrov, K. G., Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in 6-furanylquinazoline series, Bioorganic & Medicinal Chemistry Letters, Jun. 13, 2006, vol. 16, pp. 4686-4691.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib

Also Published As

Publication number Publication date
US20140024829A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
US10167275B2 (en) AZD9291 intermediate and preparation method therefor
US8563719B2 (en) Process and intermediates for preparing lapatinib
US20100197915A1 (en) Lapatinib intermediates
US8440823B2 (en) Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
CA2740977A1 (en) A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts
ZA200501892B (en) Process for the preparation of 4-(3&#39;-chloro-4&#39;-fluoroanilino) -7-methoxy-6-(3-morpholinopropoxy) quinazoline
US8859767B2 (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein
CN109134435B (en) Synthesis method of AZD9291
EP2794610B1 (en) Processes and intermediates for preparing pralatrexate
US20120245351A1 (en) Process for the preparation of lapatinib and its pharmaceutically acceptable salts
US8710221B2 (en) Process and intermediates for preparing lapatinib
TWI541235B (en) Process of preparing a quinazoline derivative
US8093384B2 (en) Processes for the preparation of alfuzosin
WO2014170910A1 (en) Process for the preparation of lapatinib
WO2022152315A1 (en) Synthesis method for aminopyrimidine fak inhibitor compound
EP1663951A2 (en) Process for the synthesis of 6-amino-4-¬(3-chloro-4-fluorophenyl)amino|-7-ethoxyquinoline-3-carbonitrile
CN104418845B (en) Prepare the method and intermediate of Lapatinib
CN112979544A (en) Preparation method of cabozantinib or salt thereof
US10392403B2 (en) Process for preparing thienopyrimidine compound and intermediates used therein
US20150065710A1 (en) Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates
US20070270589A1 (en) Quinazoline Derivative and Process for Producing the Same
TWI719620B (en) 6-AMINOPYRAZOLO[3,4-d]PYRIMIDINES AND PROCESSES FOR THEIR PREPARATION
EP3609875B1 (en) An improved process for the preparation of n-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin -4-amine dihydrochloride
TW202104164A (en) Process for the production of substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives
CN116135845A (en) Preparation method of telmisartan intermediate

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCINOPHARM TAIWAN, LTD., TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEN, YUNG-FA;HENSCHKE, JULIAN PAUL;ZHANG, XIAOHENG;AND OTHERS;SIGNING DATES FROM 20130729 TO 20130805;REEL/FRAME:031234/0886

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8